Terms: = Kidney tumors AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546 AND Treatment
21 results:
1. Circulating inflammatory cytokines in relation to the risk of renal cell carcinoma: A gender-specific two-sample Mendelian randomization study.
Tao S; Lin Y; Huang S; Lin S; Jin K; Chen H
Cancer Med; 2023 Nov; 12(22):21013-21021. PubMed ID: 37902279
[TBL] [Abstract] [Full Text] [Related]
2. Estrogen associates with female predominance in Xp11.2 translocation renal cell carcinoma.
Lu Y; Zhu Y; Ma W; Liu N; Dong X; Shi Q; Yu F; Guo H; Li D; Gan W
Sci Rep; 2023 Apr; 13(1):6141. PubMed ID: 37061606
[TBL] [Abstract] [Full Text] [Related]
3. treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.
Regan MM; Jegede OA; Mantia CM; Powles T; Werner L; Motzer RJ; Tannir NM; Lee CH; Tomita Y; Voss MH; Plimack ER; Choueiri TK; Rini BI; Hammers HJ; Escudier B; Albiges L; Huo S; Del Tejo V; Stwalley B; Atkins MB; McDermott DF
Clin Cancer Res; 2021 Dec; 27(24):6687-6695. PubMed ID: 34759043
[TBL] [Abstract] [Full Text] [Related]
4. Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer.
Uhlig A; Uhlig J; Trojan L; Woike M; Leitsmann M; Strauß A
Future Oncol; 2021 Jan; 17(1):45-56. PubMed ID: 33275038
[TBL] [Abstract] [Full Text] [Related]
5. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Saggi SS; McHenry MB; Motzer RJ
ESMO Open; 2020 Nov; 5(6):e001079. PubMed ID: 33246931
[TBL] [Abstract] [Full Text] [Related]
6. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
[TBL] [Abstract] [Full Text] [Related]
7. Association of bullous pemphigoid and comorbid health conditions: a case-control study.
Lee S; Rastogi S; Hsu DY; Nardone B; Silverberg JI
Arch Dermatol Res; 2021 Jul; 313(5):327-332. PubMed ID: 32647978
[TBL] [Abstract] [Full Text] [Related]
8. Real-world Experience With Sunitinib treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score.
Schmidinger M; Porta C; Oudard S; Denechere G; Brault Y; Serfass L; Costa N; Larkin J
Clin Genitourin Cancer; 2020 Oct; 18(5):e588-e597. PubMed ID: 32586677
[TBL] [Abstract] [Full Text] [Related]
9. Malignant Intrarenal/Renal Pelvis Paraganglioma with Co-Occurring SDHB and atrx Mutations.
Irwin T; Konnick EQ; Tretiakova MS
Endocr Pathol; 2019 Dec; 30(4):270-275. PubMed ID: 31705439
[TBL] [Abstract] [Full Text] [Related]
10. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract] [Full Text] [Related]
11. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract] [Full Text] [Related]
12. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
[TBL] [Abstract] [Full Text] [Related]
13. Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate.
Elshafei A; Tay KJ; Kara O; Malkoc E; Nyame Y; Arora H; Hatem A; Patel SA; Lugnani F; Polascik TJ; Jones JS
Clin Genitourin Cancer; 2018 Apr; 16(2):e477-e482. PubMed ID: 29174470
[TBL] [Abstract] [Full Text] [Related]
14. Malignancy in Renal Transplant Recipients Exposed to Cyclophosphamide Prior to Transplantation for the treatment of Native Glomerular Disease.
Jorgenson MR; Descourouez JL; Singh T; Astor BC; Panzer SE
Pharmacotherapy; 2018 Jan; 38(1):51-57. PubMed ID: 29136299
[TBL] [Abstract] [Full Text] [Related]
15. Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for Renal Cell Carcinoma Invading the Supradiaphragmatic Inferior Vena Cava and/or Right Atrium.
Nini A; Capitanio U; Larcher A; Dell'Oglio P; Dehò F; Suardi N; Muttin F; Carenzi C; Freschi M; Lucianò R; La Croce G; Briganti A; Colombo R; Salonia A; Castiglioni A; Rigatti P; Montorsi F; Bertini R
Eur Urol; 2018 May; 73(5):793-799. PubMed ID: 28917595
[TBL] [Abstract] [Full Text] [Related]
16. Increased Expression of Androgen Receptor mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma.
Ha YS; Lee GT; Modi P; Kwon YS; Ahn H; Kim WJ; Kim IY
J Urol; 2015 Nov; 194(5):1441-8. PubMed ID: 25796113
[TBL] [Abstract] [Full Text] [Related]
17. Quantification of peripheral blood CD133 mRNA in identifying metastasis and in predicting recurrence of patients with clear cell renal cell carcinoma.
Feng G; Jiang F; Pan C; Pu C; Huang H; Li G
Urol Oncol; 2014 Jan; 32(1):44.e9-14. PubMed ID: 24054866
[TBL] [Abstract] [Full Text] [Related]
18. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems.
Lamb GW; Aitchison M; Ramsey S; Housley SL; McMillan DC
Br J Cancer; 2012 Jan; 106(2):279-83. PubMed ID: 22166802
[TBL] [Abstract] [Full Text] [Related]
19. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience.
O'Brien MF; Rea D; Rogers E; Bredin H; Butler M; Grainger R; McDermott TE; Mullins G; O'Brien A; Twomey A; Thornhill J
Eur Urol; 2004 May; 45(5):613-8; discussion 619. PubMed ID: 15082204
[TBL] [Abstract] [Full Text] [Related]
20. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?
Leblond V; Davi F; Charlotte F; Dorent R; Bitker MO; Sutton L; Gandjbakhch I; Binet JL; Raphael M
J Clin Oncol; 1998 Jun; 16(6):2052-9. PubMed ID: 9626203
[TBL] [Abstract] [Full Text] [Related]
[Next]
